News, markets, and regulation in Europe, Asia, and South America.
February 1, 2012
By:Reflector
The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
 |
January 1, 2012
By:Reflector
A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
|
December 1, 2011
By:Reflector
The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
|
 | November 1, 2011
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
|
 | October 1, 2011
Success in the emerging markets depends significantly on navigating the myths and mental traps.
|
 | September 1, 2011
By:William Looney
Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?
|
 | September 1, 2011
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
